CARDS on the table: Should everybody with type 2 diabetes take a statin?

Current Medical Research and Opinion

Volumn 21, Issue 3, 2005, Pages 357-361

  Lee, J D ^a   Morrissey, J R ^a   Mikhailidis, D P ^b   Patel, V ^a  

^a GEORGE ELIOT HOSPITAL NHS TRUST   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Atorvastatin; Coronary events; Diabetes mellitus; Renal function; Stroke; Vascular complications

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN ANTAGONIST; ANTILIPEMIC AGENT; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

BLOOD PRESSURE MONITORING; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; ETHICS; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MICROANGIOPATHY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RETINOPATHY; REVIEW; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; STROKE; SYSTOLIC BLOOD PRESSURE;

EID: 16844364766     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X36413     Document Type: Review

References (36)

1. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease. Diabetes Care 1979;2:I20-6
2. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
4. Gæde P, Pernille V, Larsen N, et al. Multifactorial Intervention with Cardiovascular Disease in Patients with Type 2 Diabetes. N Engl J Med 2003;348:383-93
5. Lee JD, Morrissey JR, Patel V. Recalculation of cardiovascular risk score as a surrogate marker of change in clinical care of diabetes patients: the Alphabet POEM Project (Practice Of Evidence-based Medicine). Curr Med Res Opin 2004;20:765-72
6. World Health Organisation. Fact sheet no. 236. Diabetes: the cost of diabetes. Available from www.who.int/mediacentre/factsheets/fs236/en/ [Accessed 28 Jan 2005]
7. Panzram G. Mortality and survival in type 2 (non insulin-dependent) diabetes mellitus. Diabetologia 1987;30:123-31
8. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
9. UK Prospective diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in patients with type 2 diabetes (UKPDS 38). BMJ 1998;317:705-13
10. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53
11. Brenner BM, Cooper ME, de Zeeuw R, et al. Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
12. Parving H-H, Lehnert H, Brochner-Mortensen J, et al. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8
13. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
14. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: MICRO-HOPE substudy. Lancet 2000;355:253-9
15. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation 1979;59:8-13
16. Syvanne M, Taskinen MR. Lipids and lipoproteins as coronary risk factors in non-insulin dependent diabetes mellitus. Lancet 1997;350(Suppl. 1):20-3
17. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44
18. Turner RC, Millns H, Neal HAW et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998;316:823-8
19. Muldoon MF, Manuck SB, Mendelsohn AB, et al. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ 2001;322:11-5
20. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, et al. Cardiovascular events and their reduction with Pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Circulation 1998;98:2513-19
21. Pyorala K, Pedersen TR, Kjekshus J, Faegerman O, Olsson AG, Thorgerson G, et al. The Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian simvastatin survival study (4S). Diabetes Care 1997;20:614-20
22. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Education Program goal versus usual care in secondary Coronary Heart Disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2002;18:220-8
23. Athyros VG, Papageorgiou AA, Symeonidis AN, Didangelos TP, Pehlivanidis AN, Bouloukos VI, Mikhailidis DP, for the GREACE Study Collaborative Group. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology 2003;54:679-90
24. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
25. Sever PS, Dahlöf B, Poulter N, et al. Anglo-Scandinavian Cardiac Outcomes Trial - Lipid-Lowering Arm (ASCOT-LLA): Results in the subgroup of patients with diabetes. J Am Coll Cardiol 2004;43(Suppl. A):529A [882-1]
26. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42
27. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised controlled trial. Lancet 2003;361:2005-16
28. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34
29. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002;324:939-42
30. National Center for Health Statistics. Available from www.cdc.gov/nchs [Accessed 28 Jan 2005]
31. Svensson AM, Abrahamsson P, McGuire DK, Dellborg M. Influence of diabetes on long-term outcome among unselected patients with acute coronary events. Scand Cardiovasc J 2004;38:229-34
32. Wannamethee SG, Shaper AG, Lennon L. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. Heart 2004;90:1398-403
33. Murcia AM, Hennekens CH, Lamas GA, Jimenez-Navarro M, Rouleau JL, Flaker GC, Goldman S, Skali H, Braunwald E, Pfeffer MA. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med 2004;164:2273-9
34. Daskalopoulou SS, Mikkailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 2004;55:589-612
35. Klein L, Gheorghiade M. Management of the patient with diabetes mellitus and myocardial infarction: clinical trials update. Am J Med 2004;116(Suppl. 5A):47S-63
36. Patel V, Morrissey J. The Alphabet Strategy: the ABC of reducing diabetes complications. Br J Diabetes Vasc Dis 2002;2:58-9